Introduction

De Sanctis-Cacchione syndrome (DSCS) stands as one of the rarest and most severe variants of xeroderma pigmentosum (XP), a disorder rooted in faulty DNA repair mechanisms. In DSCS, the classic sun-sensitive skin presentation of XP is combined with profound neurological impairment ranging from developmental delay and intellectual disability to ataxia, hearing loss, and growth failure.¹

For paediatricians and neurologists, DSCS is particularly significant. In contrast to more familiar forms of XP, signs of DSCS typically present early in life, often in infancy or early childhood, and include microcephaly, short stature, and neurocognitive decline, in addition to the hallmark photosensitivity of the skin.² These neurological features reflect a spectrum of underlying pathology, including brain cell death (neuronal loss), peripheral neuropathy, and severe intellectual disability.

Recognising the neurological involvement of DSCS is vital not only for reaching an accurate diagnosis but also for guiding caregivers, anticipating disease progression, and planning holistic care strategies. From ensuring rigorous ultraviolet (UV) protection to monitoring developmental milestones and addressing neurocognitive needs, a comprehensive understanding of DSCS is essential for clinicians and families alike.³

Clinical overview of DSCS

Genetic basis and inheritance

DSCS is inherited in an autosomal recessive pattern and is caused by biallelic mutations (mutations in both copies of a gene) in the nucleotide excision repair (NER) pathway, which repairs DNA damage caused by UV and other environmental factors. Genes most frequently affected include XPA and ERCC2/XPD, though cases involving ERCC6/CSB or XPC have been reported.⁴ Severity often correlates with genotype: certain XPA variants produce early and profound neurodegeneration, while milder alleles may allow slower progression.

The neurological symptoms of DSCS arise because defective repair mechanisms leave neurons vulnerable to endogenous (internal) DNA damage and UV-induced lesions. Unlike keratinocytes, neurons lack robust regenerative capacity, so cumulative injury results in progressive decline.²

Distinctive clinical features

Cutaneous: Children present with striking photosensitivity, early freckling, patchy pigmentation, and accelerated actinic damage (UV skin damage). Without rigorous UV protection, they develop early-onset skin cancers, including squamous cell carcinoma, basal cell carcinoma, and melanoma, sometimes in the first decade of life.^1,3

Ocular: Ocular disease occurs alongside skin involvement: Light sensitivity (photophobia), keratitis, chronic conjunctivitis, and ocular surface neoplasia are common. These features may present before or accompany neurological signs.²

Neurological: Neurological involvement defines DSCS. Children typically show global developmental delay (GDD), intellectual disability (ID), acquired microcephaly, progressive ataxia, sensorineural hearing loss, and peripheral neuropathy. Growth failure and hypogonadism (a lack of sex hormone production during adolescence) are common. Large, long-term studies demonstrated that neurological disease commonly occurs in XPA, XPD, and XPG subtypes, while XP-E and XP-V rarely show neurodegeneration.⁴ Importantly, XP patients with neurological involvement die younger than those without, highlighting the prognostic weight of DSCS.

Distinction from other XP subtypes

Compared with “classic” XP, DSCS is marked by earlier onset and more severe neurological decline, often beginning in infancy or toddler years. The three main symptoms (clinical triad) – microcephaly, intellectual disability, and growth/endocrine abnormalities – are far more typical of DSCS than of other subtypes.³ Genotype–phenotype correlation further assists differentiation: XPA and XPD mutations most often produce DSCS, whereas XP-V and XP-E are usually neurologically spared.⁴

Neurological manifestations in children

Key features:

• Microcephaly is a hallmark symptom, often recognised in early childhood and defined by head circumference below normal standards
• Seizures may occur, though less consistently. Case reports describe children with myoclonic seizures and rapid neurological decline, showing how epilepsy is part of the syndrome’s spectrum
• Peripheral neuropathy is well documented, with nerve biopsies showing loss of myelinated fibres and Schwann cell degeneration, correlating with reduced nerve conduction velocities
• Other manifestations include ataxia, spasticity, and movement disorders such as choreoathetosis, reported in both pediatric and adult cases^2,4

Association with developmental delay

Neurological impairments almost always accompany developmental delay and intellectual disability. DNA repair defects lead to incrasing neural injury, resulting in progressive loss of cognitive and motor skills. In practice, these deficits mean delayed walking, late or absent speech, and regression of acquired abilities.^2,3

Onset and progression

Symptoms typically emerge within the first years of life. Historical reports from 1932 documented infants with microcephaly and early neurocognitive decline. Some children lose motor and feeding abilities within months, while others show gradual deterioration across years. Rare late-onset presentations have been described in adulthood, suggesting heterogeneity in progression. Nonetheless, early, relentless decline remains the rule in DSCS.^1,2

Developmental delay and intellectual disability

Definitions

• Developmental delay: lag in achieving expected milestones across domains (motor, cognitive, language, social)
• Intellectual disability: broader and persistent limitations in reasoning, problem-solving, and adaptive behaviour²

In DSCS, developmental delay often evolves into intellectual disability as neuronal injury accumulates.³

Mechanisms

Defective nucleotide excision repair compromises the removal of both UV-related and endogenous DNA lesions. Neurons accumulate unrepaired lesions, leading to dysfunction and neural death. The degree of impairment correlates with severity: children with near-complete loss of repair capacity show profound intellectual disability and early regression, while partial function may allow slower deterioration.⁴

Clinical spectrum

Cognitive impairment in DSCS spans a continuum:

• Some children show moderate delays with slower speech or motor development
• Others display significant intellectual disability, with regression of skills and dependence for daily living

Historical data emphasise the prominence of neurocognitive involvement: among hundreds of XP cases, the majority with neurological disease had significant intellectual disability, often accompanied by ataxia and microcephaly.

When to suspect DSCS?

Think DSCS when a child has the classic UV damage signs of xeroderma pigmentosum (early freckling, extreme sun sensitivity, premalignant or malignant skin lesions at a young age) plus one or more neurological warning signs: developmental regression or global developmental delay, microcephaly, ataxia, new-onset or refractory seizures, sensorineural hearing loss, or progressive motor weakness/neuropathy. A family history including closely related family members or similarly affected siblings strengthens the suspicion.² Early recognition matters because neurological involvement changes prognosis and management.

Neurodevelopmental evaluation – practical tools

A structured assessment is essential and should include:

• Standardised developmental screening for young children to detect delays early
• For GDD or suspected ID, formal cognitive testing (age-appropriate IQ or developmental quotient instruments) and adaptive-function assessments are indicated once the child is testable
• Motor assessments: the Scale for the Assessment and Rating of Ataxia (SARA) for ataxia, when indicated, neurophysiology (nerve conduction studies/electromyography (EMG) when peripheral neuropathy is suspected), and audiology/vision testing should be part of the baseline work-up
• Use of multidisciplinary developmental clinics or pathways ensures coordinated serial reassessments – GDD often evolves into established ID and needs re-evaluation over time³

Role of genetic testing

Molecular confirmation by identifying the affected mutation variants in XP-associated genes (most commonly XPA, XPD/ERCC2, XPG/ERCC5 for neurologically severe phenotypes) is the diagnostic gold standard. Genetic testing:

• Confirms the diagnosis and helps define prognosis (certain variants have a higher risk of neurodegeneration)
• Guides testing and reproductive counselling for families
• May increase monitoring intensity for skin, eye and neurological complications⁴

Value of multidisciplinary assessment

As DSCS requires input from various specialists (dermatologists, neurologists, opthamologists and paediatrc psychologists), coordinated care is essential. Multidisciplinary teams provide:

• Holistic baseline evaluation and individualised monitoring plans
• Timely therapeutic referrals (e.g., physiotherapy, speech and language therapy)
• Family support and genetic counselling. Early involvement of social work and educational specialists eases long-term planning^2,3

Management and supportive care

Principles of care

DSCS has no cure. Management focuses on preventing UV-induced damage, treating cancers promptly, and supporting neurological and developmental function.^1,3

Core strategies

• UV protection and dermatologic care: strict sunlight avoidance with protective clothing, sunscreens, window films, and frequent dermatologic reviews. Suspicious lesions require early biopsy
• Early intervention therapies: speech, occupational, and physiotherapy maximise communication, motor skills, and independence
• Neurological management: seizures are treated per standard paediatric protocols; spasticity, pain, and contractures require therapy and medications as needed. Neurorehabilitation input is crucial
• Educational planning: individualised education programs and adaptive learning environments help children with even mild impairments reach their potential
• Family counselling and genetics: families need empathetic explanation of the autosomal recessive inheritance, recurrence risks, and reproductive options. Carrier testing and psychosocial support should be offered^2,4

Lifelong monitoring

Children with DSCS require lifelong monitoring for both skin and neurological complications. Dermatologic and ophthalmic evaluations detect early malignancy, while neurodevelopmental monitoring allows timely adjustments to therapies and support. It is important to conduct regular assessments of hearing and vision, as well as to monitor motor and cognitive abilities. Multidisciplinary clinics are best suited to coordinate this care.^1,3

FAQs

What are the main signs of DSCS in children?

Children typically show extreme sun sensitivity, early freckling or skin cancers, microcephaly, growth delays, and neurological issues such as developmental delay and intellectual disability.

Why do children with DSCS develop intellectual disability?

Defective DNA repair in DSCS causes cumulative damage to neurons, leading to cognitive decline, delayed milestones, and, in severe cases, profound intellectual disability.

How is DSCS diagnosed in children?

Diagnosis is based on early skin and neurological signs, confirmed by genetic testing for mutations in XP-related genes. Multidisciplinary developmental assessments help evaluate cognitive and motor function.

What treatments or interventions are available?

There is no cure. Management focuses on strict UV protection, early cancer detection, supportive therapies (speech, occupational, physical), seizure management, and individualised educational and family support.

Summary

De Sanctis-Cacchione syndrome represents the intersection of dermatology and neurology within a single genetic disorder. Developmental delay and intellectual disability are central to its burden, profoundly shaping prognosis and family experience. While no cure exists, timely recognition, genetic confirmation, and multidisciplinary care can improve outcomes by preventing skin cancers, supporting neurodevelopment, and guiding families.

Future work should explore neuroprotective strategies and genetic therapies to alter the disease course. Until then, care must remain holistic, family-centred, and proactive, addressing both the dermatologic and neurological presentations of this rare but devastating syndrome.^1,4